• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

建立和维护 PBMC 库，以支持临床疫苗试验的功能细胞研究。

Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.

机构信息

Foundation for National Institutes of Health, Bethesda, MD, USA.

Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Duke University Medical Center, Durham, NC, USA.

出版信息

J Immunol Methods. 2014 Jul;409:107-16. doi: 10.1016/j.jim.2014.04.005. Epub 2014 Apr 29.

DOI:10.1016/j.jim.2014.04.005
PMID:24787274
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4152919/
Abstract

A large repository of cryopreserved peripheral blood mononuclear cells (PBMCs) samples was created to provide laboratories testing the specimens from human immunodeficiency virus-1 (HIV-1) vaccine clinical trials the material for assay development, optimization, and validation. One hundred thirty-one PBMC samples were collected using leukapheresis procedure between 2007 and 2013 by the Comprehensive T cell Vaccine Immune Monitoring Consortium core repository. The donors included 83 human immunodeficiency virus-1 (HIV-1) seronegative and 32 HIV-1 seropositive subjects. The samples were extensively characterized for the ability of T cell subsets to respond to recall viral antigens including cytomegalovirus, Epstein-Barr virus, influenza virus, and HIV-1 using Interferon-gamma (IFN-γ) enzyme linked immunospot (ELISpot) and IFN-γ/interleukin 2 (IL-2) intracellular cytokine staining (ICS) assays. A subset of samples was evaluated over time to determine the integrity of the cryopreserved samples in relation to recovery, viability, and functionality. The principal results of our study demonstrate that viable and functional cells were consistently recovered from the cryopreserved samples. Therefore, we determined that this repository of large size cryopreserved cellular samples constitutes a unique resource for laboratories that are involved in optimization and validation of assays to evaluate T, B, and NK cellular functions in the context of clinical trials.

摘要

建立了一个大型冷冻外周血单核细胞（PBMC）样本库，为检测人类免疫缺陷病毒-1（HIV-1）疫苗临床试验标本的实验室提供了材料，用于检测开发、优化和验证。2007 年至 2013 年期间，综合 T 细胞疫苗免疫监测联盟核心库通过白细胞分离术收集了 131 份 PBMC 样本。供体包括 83 名 HIV-1 血清阴性和 32 名 HIV-1 血清阳性的受试者。使用干扰素-γ（IFN-γ）酶联免疫斑点（ELISpot）和 IFN-γ/白细胞介素 2（IL-2）细胞内细胞因子染色（ICS）检测，对这些样本进行了广泛的特征分析，以评估 T 细胞亚群对病毒抗原（包括巨细胞病毒、EB 病毒、流感病毒和 HIV-1）的反应能力。一部分样本随着时间的推移进行了评估，以确定冷冻保存样本在恢复、活力和功能方面的完整性。我们的研究的主要结果表明，从冷冻保存的样本中可以持续回收有活力和功能的细胞。因此，我们确定这个大规模冷冻细胞样本库是一个独特的资源，为参与优化和验证评估 T、B 和 NK 细胞功能的实验室提供了资源，这些实验室涉及临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/c9af3f2959ad/nihms617359f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/4f7821583314/nihms617359f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/c99f451c2ac4/nihms617359f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/d3f56958dcf6/nihms617359f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/93f89237a6a6/nihms617359f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/ca55b98b504d/nihms617359f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/c9af3f2959ad/nihms617359f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/4f7821583314/nihms617359f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/c99f451c2ac4/nihms617359f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/d3f56958dcf6/nihms617359f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/93f89237a6a6/nihms617359f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/ca55b98b504d/nihms617359f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769a/4152919/c9af3f2959ad/nihms617359f6.jpg

相似文献

1
Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.建立和维护 PBMC 库，以支持临床疫苗试验的功能细胞研究。
J Immunol Methods. 2014 Jul;409:107-16. doi: 10.1016/j.jim.2014.04.005. Epub 2014 Apr 29.
2
The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.HIV/AIDS 疫苗免疫学研究中心（CHAVI）用于冷冻保存人外周血单个核细胞的多站点质量保证计划。
J Immunol Methods. 2014 Jul;409:21-30. doi: 10.1016/j.jim.2014.05.013. Epub 2014 Jun 5.
3
Development of a contemporary globally diverse HIV viral panel by the EQAPOL program.EQAPOL 项目开发的当代全球多样化 HIV 病毒面板。
J Immunol Methods. 2014 Jul;409:117-30. doi: 10.1016/j.jim.2014.01.004. Epub 2014 Jan 19.
4
Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.利用集成的、基于网络的分析门户，为覆盖 28 个临床试验站点的冷冻 PBMC 实施全面质量计划的益处。
J Immunol Methods. 2014 Jul;409:9-20. doi: 10.1016/j.jim.2014.03.024. Epub 2014 Apr 4.
5
Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs.制备用于支持能力验证计划的质量控制材料的 Leukopak PBMC 样品处理。
J Immunol Methods. 2014 Jul;409:99-106. doi: 10.1016/j.jim.2014.05.019. Epub 2014 Jun 10.
6
Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL).在外部质量保证计划监督实验室（EQAPOL）中实施良好临床实验室实践（GCLP）指南。
J Immunol Methods. 2014 Jul;409:91-8. doi: 10.1016/j.jim.2013.09.012. Epub 2013 Oct 9.
7
Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies.《免疫学方法杂志》特刊介绍：建立全球资源计划，以支持艾滋病毒/艾滋病临床试验研究。
J Immunol Methods. 2014 Jul;409:1-5. doi: 10.1016/j.jim.2014.05.016. Epub 2014 Jun 6.
8
The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.干扰素-γ 酶联免疫斑点（IFN-γ ELISpot）检测外部质量保证监督实验室（EQAPOL）能力验证计划。
J Immunol Methods. 2014 Jul;409:31-43. doi: 10.1016/j.jim.2014.03.017. Epub 2014 Mar 28.
9
Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry.用于评估 EQAPOL 能力验证的统计方法：ELISpot、Luminex 和流式细胞术。
J Immunol Methods. 2014 Jul;409:72-81. doi: 10.1016/j.jim.2014.01.007. Epub 2014 Jan 20.
10
Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays.致力于建立多功能细胞内细胞因子染色分析检测的全面外部质量保证计划。
J Immunol Methods. 2014 Jul;409:44-53. doi: 10.1016/j.jim.2014.05.021. Epub 2014 Jun 23.

引用本文的文献

1
Preservation of functionality, immunophenotype, and recovery of HIV RNA from PBMCs cryopreserved for more than 20 years.超过 20 年冻存的 PBMCs 中 HIV RNA 的功能、免疫表型保存和恢复。
Front Immunol. 2024 Aug 16;15:1382711. doi: 10.3389/fimmu.2024.1382711. eCollection 2024.
2
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.病毒载体递送免疫原可集中 HIV-1 抗体特异性，并增加循环抗体回忆反应的持久性。
PLoS Pathog. 2023 May 31;19(5):e1011359. doi: 10.1371/journal.ppat.1011359. eCollection 2023 May.
3
Validation of the performance and suitability of a new class of FBS optimized for use in single-cell functional assays.

本文引用的文献

1
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses.人类循环 PD-1+CXCR3-CXCR5+记忆性滤泡辅助 T 细胞具有高度功能性，与广泛中和 HIV 抗体反应相关。
Immunity. 2013 Oct 17;39(4):758-69. doi: 10.1016/j.immuni.2013.08.031. Epub 2013 Sep 12.
2
Structured reporting of T cell assay results.T细胞检测结果的结构化报告。
Cancer Immun. 2013 Jul 15;13:13. Print 2013.
3
Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials.
验证一种新型 FBS 的性能和适用性，该 FBS 经过优化可用于单细胞功能测定。
J Immunol Methods. 2023 Apr;515:113452. doi: 10.1016/j.jim.2023.113452. Epub 2023 Feb 28.
4
Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.疫苗诱导的、具有 Fc 介导的效应功能的高滴度 HIV Env 特异性抗体不足以保护婴儿恒河猴免受口服 SHIV 感染。
mSphere. 2022 Feb 23;7(1):e0083921. doi: 10.1128/msphere.00839-21.
5
Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features.独特的生物物理抗体特征可预测多样化的抗病毒 IgG 效应活性。
Retrovirology. 2021 Oct 30;18(1):35. doi: 10.1186/s12977-021-00579-9.
6
Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Model of () Infection.唑类口服药物与米替福新联合治疗 () 感染模型的效价和临床前证据。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0142521. doi: 10.1128/AAC.01425-21. Epub 2021 Oct 25.
7
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.脂质纳米颗粒包裹的核苷修饰mRNA疫苗在非人灵长类动物中引发的多功能HIV-1抗体与蛋白质相当。
NPJ Vaccines. 2021 Apr 9;6(1):50. doi: 10.1038/s41541-021-00307-6.
8
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers.在健康非洲志愿者中，HIV-DNA 接种后再接种 HIV-MVA（无论有无 CN54rgp140/GLA-AF）诱导的频繁抗 V1V2 反应。
Microorganisms. 2020 Nov 4;8(11):1722. doi: 10.3390/microorganisms8111722.
9
SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.SMAC 模拟物增强型三联双特异性 HIVxCD3 重定向分子在感染 SHIV.C.CH505、抗逆转录病毒治疗抑制的恒河猴中的作用。
J Virol. 2020 Oct 14;94(21). doi: 10.1128/JVI.00793-20.
10
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.3M-052，一种合成的 TLR-7/8 激动剂，可在非人类灵长类动物中诱导持久的 HIV-1 包膜特异性浆细胞和体液免疫。
Sci Immunol. 2020 Jun 19;5(48). doi: 10.1126/sciimmunol.abb1025.
用于检测 HIV 疫苗试验中疫苗诱导的记忆应答的记忆 B 细胞 ELISpot 的优化和鉴定。
J Immunol Methods. 2013 Aug 30;394(1-2):84-93. doi: 10.1016/j.jim.2013.05.007. Epub 2013 May 23.
4
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.巨细胞病毒载体违反 CD8+ T 细胞表位识别模式。
Science. 2013 May 24;340(6135):1237874. doi: 10.1126/science.1237874.
5
Complex correlates of protection after vaccination.接种疫苗后的复杂保护相关因素。
Clin Infect Dis. 2013 May;56(10):1458-65. doi: 10.1093/cid/cit048. Epub 2013 Feb 5.
6
The T-cell response to HIV.HIV 的 T 细胞免疫应答
Cold Spring Harb Perspect Med. 2012 Nov 1;2(11):a007054. doi: 10.1101/cshperspect.a007054.
7
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.HIV-1 抗体：感染与疫苗接种的启示，有助于指导疫苗设计。
Trends Microbiol. 2012 Nov;20(11):532-9. doi: 10.1016/j.tim.2012.08.011. Epub 2012 Sep 13.
8
T cell assays and MIATA: the essential minimum for maximum impact.T细胞检测与MIATA：实现最大影响力的基本要素。
Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010.
9
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
10
International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.国际技术转移：符合 GCLP 的 HIV-1 中和抗体检测用于人体临床试验。
PLoS One. 2012;7(1):e30963. doi: 10.1371/journal.pone.0030963. Epub 2012 Jan 27.